HOME >> MEDICINE >> NEWS
Three Harvard Medical School endowed chairs named simultaneously in sleep medicine

Boston, MA - May 11, 2004 - Harvard Medical School (HMS) is taking steps to dramatically advance the field of Sleep Medicine through the simultaneous establishment of three endowed chairs all devoted to this emerging critical field of medicine.

Joseph B. Martin, Dean of HMS, hailed today's announcement as an historic moment for the school and in the evolution of the field of Sleep Medicine. "This generous and timely support will greatly accelerate advances in sleep and circadian rhythm research. At a time when nearly 40 million Americans suffer with sleep disorders, many find numerous barriers to diagnosis and treatment," said Martin, MD, PhD. "These gifts will enable HMS to take a leading role in this interdisciplinary field, ensuring the advancement of scientific research and the development of new treatments for sleep disorders."

The three chairs are named after the founders and Chairmen of three publicly listed companies that have been innovators in sleep therapy: Dr. Frank Baldino, CEO of Cephalon, Inc., Mr. Gerald E. McGinnis, Board Chairman, of Respironics, and Dr. Peter C. Farrell, CEO of ResMed. Each chair was funded by unrestricted gifts from their companies or themselves.

Recognizing the importance of this scientific discipline, Martin established the Division of Sleep Medicine at HMS in 1997. "The goal of the HMS Division of Sleep Medicine has been to establish sleep disorders medicine as a formally recognized medical discipline, and to forge a path of discovery while providing training for the next generation of national leaders in this discipline," said Martin.

President of Brigham and Women's Hospital, Gary Gottlieb, MD, MBA, concurs, "These three chairs will positively impact research and clinical treatments for dangerous and disabling sleep disorders," he said. "The professorships are being created in honor of visionary leaders in the health care industry."

Martin said that the three men whose names will be on
'"/>

Contact: Judith Montminy
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
11-May-2004


Page: 1 2 3 4 5

Related medicine news :

1. Three-year cervical cancer screening recommendations may be applicable for certain women with HIV
2. Three anti-platelet drugs used in combination are safe
3. Three out of the four million newborn babies who die each year could be saved
4. Three-year health study of teenage girls is underway at Trenton Central High School
5. Three months is too soon to judge a CML patients response to Gleevec, researchers find
6. Three Abbott chemists honored as Heroes for development of HIV therapy for children
7. Three Pfizer Inc chemists win Heroes award for epilepsy treatment for children, adults
8. Three Merck chemists win Heroes of Chemistry award for major asthma treatment advance
9. Three-time Emmy Award winning actress Kathy Baker to participate in ADHD experts on call program
10. Three-month antibiotic treatment reduces risk of future heart attack
11. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference

Post Your Comments:
(Date:7/2/2015)... ... July 02, 2015 , ... Maddock Douglas is ... and business models. To help manage the increasing demand for innovation as a ... as SVP of Strategic Engagements. , Benkendorf is a seasoned management executive with ...
(Date:7/1/2015)... Mich. (PRWEB) , ... July 01, 2015 , ... ... transition of Catholic sponsorship complete, St. Joseph’s Health, located in Syracuse, N.Y., is ... the closing today, we have gained an admirable and important partner committed to ...
(Date:7/1/2015)... New York, New York (PRWEB) , ... July ... ... drug injury lawsuit filed against the manufacturers of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has ... the U.S. District Court, Southern District of West Virginia on June 26th, the ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced that they will welcome four new members to their ...
(Date:7/1/2015)... ... July 01, 2015 , ... A ... organically raised chickens and eggs. Eating organic foods and products can help limit ... more environmentally friendly than production chicken farming. Choosing home raised chickens and eggs ...
Breaking Medicine News(10 mins):Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2
(Date:7/1/2015)... , July 1, 2015  AVACEN, Inc. announced today the ... patent covering the medical technology platform supporting its unique Dry ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... methods patent no. 9,066,781 - Methods And Apparatus For Therapeutic ... AVACEN and specific methods of use, referred to by the ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek ... company focused on chronic inflammatory disease and neurologic disorders, ... principle study with anatabine citrate, the Company,s lead compound. ... dose of anatabine citrate can significantly inhibit the activation ... The Company is developing this compound in a Phase ...
(Date:7/1/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... president and chief executive officer, is scheduled to ... provide an update on Egalet,s marketed product ... approved product OXAYDO ™ (oxycodone HCI, USP) ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3
Cached News: